LATEST NEWS
Read our latest news, blog posts and research updates.
SIOPEN AGM, Jerusalem, October 2018
The International Society of Paediatric Oncology, European Neuroblastoma (SIOPEN), is the grouping of neuroblastoma clinicians from Europe and other affiliated countries. Their major yearly meeting is the Autumn AGM, this year hosted by Dr Isaac Yaniv and Dr Shifra Ash in Jerusalem. Here we report on the major themes of the meeting, focusing on current and recent clinical trials run within SIOPEN.
Scottish Medicines Consortium approves Dinutuximab beta
NICE - final guidance on Dinutuximab beta
The final guidance on the use of Dinutuximab beta for treating high risk neuroblastoma has been published by NICE. Visit their website for details.
Neuroblastoma UK 2018 Research Grant Round opens
Neuroblastoma UK announces the opening of its 2018 research grant round. Applications are invited for UK or Republic of Ireland (ROI) led research that will benefit children with neuroblastoma.
NICE approves neuroblastoma drug
Neuroblastoma UK has welcomed today’s announcement by the National Institute for Health and Care Excellence (NICE) that it has approved Dinutuximab beta for funding in the NHS.
Update - NICE decision re Dinutuximab beta
Update on today’s meeting with NICE re Dinutuximab beta.
Neuroblastoma charities unite to beat cancer
After working with the great team at Smile with Siddy supporting research projects together, we are pleased to announce they are joining us at Neuroblastoma UK.
Formalising our collaboration means that we combine our respective strengths and shared belief of driving forward research. We are also delighted that Flora Cahill, Chair of Smile with Siddy, will join Neuroblastoma UK as one of our trustees. Flora brings a wealth of fundraising expertise and driving awareness of neuroblastoma to enable us to continue fund ground breaking research
NBUK statement on NICE decision not to fund Dinutuximab beta for children
Statement by Neuroblastoma UK in response to the decision by NICE not to fund Dinutuximab beta for children.
NBUK Announces New Chair
After an outstanding 16 months as Acting Chair, Guy Blanchard is returning to his position as Research Trustee. Guy took on the role in January 2017 and hands over to our new Chair, Tony Heddon. We would like to thank Guy, and congratulate Tony, both continue to make amazing contributions.
Message from our outgoing Chair
Research Trustee Guy Blanchard took on the role of Acting Chair in January 2017, to drive forward our role in funding the best UK collaborative research to find new and kinder treatments so that all children survive neuroblastoma.
We are enormously grateful to Guy for taking on this position and for his calm and thoughtful leadership and we send our thanks to him. As he returns to his research role, we look forward to his continued contribution to the charity.
Read more about his time as Acting Chair and why his priority is to ensure we remain an independent and experienced voice to represent children with this devastating disease.